Johann Gudjonsson
University of Michigan
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
5
all conditions, ClinicalTrials.gov
NIH grants tied to them
10
2 more share only the name and are not shown
Trial papers
18
PubMed author-name match
Trials
Studies that name Johann Gudjonsson as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:17 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT05268107 · Ethnic Differences in Mechanisms of Action of DupilumabUniversity of Michigan · recruiting · Atopic Dermatitis · principal investigator
- N/ANCT03048721 · Skin Tape Harvesting for Transcriptomics AnalysisUniversity of Michigan · completed · Psoriasis · principal investigator
- Ph2NCT02622386 · The Effect of Riboflavin on Moderate to Severe Plaque Type PsoriasisUniversity of Michigan · completed · Psoriasis · principal investigator
- Ph4NCT01971346 · The Immunological Basis for Treatment Resistance to Anti-TNF TreatmentsUniversity of Michigan · completed · Psoriasis · principal investigator
- Ph2NCT01384630 · Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe PsoriasisJanssen Research & Development, LLC · completed · Psoriasis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- High performance wearable body odor sensor arrays for disease detection and monitoringU01TR004066 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2022 to 2026 · $1,154,765 awarded in 2026Same name and institution; not confirmed by an ID
- Immunogenomics and Systems Biology CoreUC2AR081033 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2022 to 2026 · $1,057,514 awarded in 2026Same name and institution; not confirmed by an ID
- Integrated Program for Cutaneous Immune-Stromal Interactions in SLE (IPCISS)P01AI179251 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2025 to 2026 · $1,520,330 awarded in 2026Same name and institution; not confirmed by an ID
- Role of the Hippo pathway in scleroderma pathogenesisR01AI183620 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2024 to 2026 · $601,644 awarded in 2026Same name and institution; not confirmed by an ID
- Role of the sex biased transcription factor VGLL3 in promoting autoimmune responses in SLER01AI130025 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2017 to 2026 · $465,237 awarded in 2026Same name and institution; not confirmed by an ID
- University of Michigan MHWFAC CoFar CMC Center ApplicationU01AI181882 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2024 to 2026 · $380,000 awarded in 2026Same name and institution; not confirmed by an ID
- University of Michigan Skin Biology and Diseases Resource-based CenterP30AR075043 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2019 to 2026 · $720,722 awarded in 2026Same name and institution; not confirmed by an ID
- Epigenetic regulation of sexually dimorphic immune responses in keratinocytesR21AR077741 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2021 to 2022 · $169,884 awarded in 2022Same name and institution; not confirmed by an ID
- Role of IL-13 and the IL-13 Associated rs20541 Risk Variant in the Pathogenesis of PsoriasisR01AR069071 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2015 to 2019 · $406,870 awarded in 2019Same name and institution; not confirmed by an ID
- Role of the Psoriasis Associated IL23R Risk Variants on Th17 Biology and FunctionK08AR060802 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2011 to 2015 · $126,900 awarded in 2015Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:17 UTC. The ranking covers the 200 most relevant of 18 PubMed records, and a shared surname and initials can bring in a namesake. All 18 on PubMed
- Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study.Br J Dermatol · 2003156 citationsRCR 3.7
- Human plasma-derived mannose-binding lectin: a phase I safety and pharmacokinetic study.Scand J Immunol · 200482 citationsRCR 2.1
- Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial.JCI Insight · 202271 citationsRCR 5.8
- 65 citationsRCR 2.0
- Modulation of epidermal transcription circuits in psoriasis: new links between inflammation and hyperproliferation.PLoS One · 201350 citationsRCR 1.7
- Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial.Br J Dermatol · 202346 citationsRCR 6.2
- Patient-reported Outcomes and Clinical Response in Patients with Moderate-to-severe Plaque Psoriasis Treated with Tonsillectomy: A Randomized Controlled Trial.Acta Derm Venereol · 201732 citationsRCR 1.4
- Open-Label Trial of MABp1, a True Human Monoclonal Antibody Targeting Interleukin 1α, for the Treatment of Psoriasis.JAMA Dermatol · 201525 citationsRCR 0.8
- Rapid response of lichen planus to baricitinib associated with suppression of cytotoxic CXCL13+CD8+ T cells.J Clin Invest · 202418 citationsRCR 2.6
- Topical Ruxolitinib in the Treatment of Necrobiosis Lipoidica: A Prospective, Open-Label Study.J Invest Dermatol · 202410 citationsRCR 2.2